银屑病生物制剂治疗前3年药物存活率:剂量升级或停药复合终点
基于丹麦全国前瞻性登记(DERMBIO,2007-2019)纳入4313个治疗序列,比较阿达木单抗、司库奇尤单抗和乌司奴单抗治疗银屑病的真实世界表现。复合终点(超说明书剂量升级或停药)风险司库奇尤单抗低于乌司奴单抗(HR 0.66),阿达木单抗高于乌司奴单抗(HR 1.15);但停药风险司库奇尤单抗(HR 1.24)和阿达木单抗(HR 2.01)均高于乌司奴单抗。
要点
- 复合终点风险:司库奇尤单抗低于乌司奴单抗(HR 0.66),阿达木单抗高于乌司奴单抗(HR 1.15)。
- 停药风险:司库奇尤单抗(HR 1.24)和阿达木单抗(HR 2.01)均高于乌司奴单抗。
- 生物制剂初治患者中,司库奇尤单抗停药风险与乌司奴单抗相当(HR 0.95)。
核心结论
- 以超说明书剂量升级或停药为复合终点评估生物制剂真实世界表现时,司库奇尤单抗风险低于乌司奴单抗,阿达木单抗风险高于乌司奴单抗。
- 但单独停药风险司库奇尤单抗和阿达木单抗均高于乌司奴单抗。
- 生物制剂初治患者中司库奇尤单抗停药风险与乌司奴单抗相当。
研究设计与样本
- 基于丹麦全国前瞻性登记DERMBIO(2007-2019)的队列研究。
- 纳入接受阿达木单抗、司库奇尤单抗和/或乌司奴单抗治疗的银屑病患者,共4313个治疗序列。
- 人群特征:女性38.8%,平均年龄46.0岁,生物制剂初治58.3%。
- 主要终点为超说明书剂量升级或停药的复合终点,次要终点分别为剂量升级和停药。
主要发现
- 复合终点风险:司库奇尤单抗 vs 乌司奴单抗 HR 0.66(95%CI 0.59-0.76),阿达木单抗 vs 乌司奴单抗 HR 1.15(95%CI 1.05-1.26)。
- 停药风险:司库奇尤单抗 vs 乌司奴单抗 HR 1.24(95%CI 1.08-1.42),阿达木单抗 vs 乌司奴单抗 HR 2.01(95%CI 1.82-2.22)。
- 生物制剂初治患者中,司库奇尤单抗 vs 乌司奴单抗停药风险 HR 0.95(95%CI 0.61-1.49)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The real-world efficacy of biologics may be insufficiently assessed through common drug survival studies. The objective was thus to examine the real-world performance of biologics in the treatment of psoriasis using the composite endpoint of either discontinuation or off-label dose escalation. Using a prospective nationwide registry (DERMBIO, 2007-2019), we included patients with psoriasis treated with adalimumab, secukinumab, and/or ustekinumab, which have all been used as first-line therapy during the inclusion period. The primary endpoint was a composite of either off-label dose escalation or discontinuation of treatment, whereas the secondary outcomes were dose escalation and discontinuation, respectively. Kaplan-Meier curves were used for the presentation of unadjusted drug survival curves. Cox-regression models were used for risk assessment. In 4,313 treatment series (38.8% women, mean age 46.0 years, and 58.3% bio-naivety), we found that the risk of the composite endpoint was lower for secukinumab when compared with ustekinumab (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.59-0.76), but higher for adalimumab (HR 1.15, 95% CI 1.05-1.26). However, the risk of discontinuation was higher for secukinumab (HR 1.24, 95% CI 1.08-1.42) and adalimumab (HR 2.01, 95% CI 1.82-2.22). For bio-naive patients treated with secukinumab, the risk of discontinuation was comparable to that of ustekinumab (HR 0.95, 95% CI 0.61-1.49).
引用
- Thein D, Rosenø NAL, Maul JT, et al. Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment - a Nationwide Cohort Study. J Invest Dermatol. 2023. PMID: 37119965. doi:10.1016/j.jid.2023.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。